Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort

Naomi E. Wijker, Suzanna Vidmar, Keith Grimwood, Peter D. Sly, Catherine A. Byrnes, John B. Carlin, Peter J. Cooper, Colin F. Robertson, R. John Massie, Mariette P.C. Kemner van de Corput, Joyce Cheney, Harm A.W.M. Tiddens, Claire E. Wainwright for the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) and Follow-up of the ACFBAL (CF-FAB) study groups
European Respiratory Journal 2020 55: 1901694; DOI: 10.1183/13993003.01694-2019
Naomi E. Wijker
1Pulmonology and Allergology, Erasmus Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands
2Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
13N.E. Wijker and S. Vidmar contributed equally to this paper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanna Vidmar
3Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia
4Dept of Paediatrics, University of Melbourne, Melbourne, Australia
13N.E. Wijker and S. Vidmar contributed equally to this paper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Grimwood
5School of Medicine and Menzies Health Institute Queensland, Griffith University Gold Coast Campus, Gold Coast, Australia
6Depts of Infectious Diseases and Paediatrics, Gold Coast Health, Gold Coast, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter D. Sly
7Child Health Research Centre, The University of Queensland, Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine A. Byrnes
8Starship Children's Health and Dept of Paediatrics, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John B. Carlin
3Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia
4Dept of Paediatrics, University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Cooper
9Dept of Respiratory and Sleep Medicine, The Children's Hospital at Westmead, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin F. Robertson
10Dept of Respiratory Medicine, Royal Children's Hospital, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. John Massie
10Dept of Respiratory Medicine, Royal Children's Hospital, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariette P.C. Kemner van de Corput
1Pulmonology and Allergology, Erasmus Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands
2Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce Cheney
11Dept of Respiratory and Sleep Medicine, Queensland Children's Hospital, Brisbane, Australia
12School of Medicine, The University of Queensland, Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harm A.W.M. Tiddens
1Pulmonology and Allergology, Erasmus Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands
14H.A.W.M. Tiddens and C.E. Wainwright contributed equally to this paper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: h.tiddens@erasmusmc.nl
Claire E. Wainwright
11Dept of Respiratory and Sleep Medicine, Queensland Children's Hospital, Brisbane, Australia
12School of Medicine, The University of Queensland, Brisbane, Australia
14H.A.W.M. Tiddens and C.E. Wainwright contributed equally to this paper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Claire E. Wainwright
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Little is known about early predictors of later cystic fibrosis (CF) structural lung disease. This study examined early predictors of progressive structural lung abnormalities in children who completed the Australasian CF Bronchoalveolar Lavage (ACFBAL) clinical trial at age 5-years and participated in an observational follow-up study (CF-FAB).

Eight Australian and New Zealand CF centres participated in CF-FAB and provided follow-up chest computed-tomography (CT) scans for children who had completed the ACFBAL study with baseline scans at age 5-years. CT scans were annotated using PRAGMA-CF scoring. Ordinal regression analysis and linear regression were used to investigate associations between PRAGMA-CF (Perth–Rotterdam Annotated Grid Morphometric Analysis for CF) outcomes at follow-up and variables measured during the ACFBAL study.

99 out of 157 ACFBAL children (mean±sd age 13±1.5 years) participated in the CF-FAB study. The probability of bronchiectasis at follow-up increased with airway disease severity on the baseline CT scan. In multiple regression (retaining factors at p<0.05) the extent of bronchiectasis at follow-up was associated with baseline atelectasis (OR 7.2, 95% CI 2.4–22; p≤ 0.001), bronchoalveolar lavage (BAL) log2 interleukin (IL)-8 (OR 1.2, 95% CI 1.05–1.5; p=0.010) and body mass index z-score (OR 0.49, 95% CI 0.24–1.00; p=0.05) at age 5 years. Percentage trapped air at follow-up was associated with BAL log2 IL-8 (coefficient 1.3, 95% CI 0.57–2.1; p<0.001) at age 5 years.

The extent of airway disease, atelectasis, airway inflammation and poor nutritional status in early childhood are risk factors for progressive structural lung disease in adolescence.

Abstract

In children with cystic fibrosis, airways disease severity on chest computed tomography at age 5 years increased the risk of bronchiectasis in adolescence and its extent was predicted by poorer nutrition, airway inflammation, and atelectasis http://bit.ly/2Nnk8LW

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • This article has an editorial commentary: https://doi.org/10.1183/13993003.00105-2020

  • The following investigators constitute the ACFBAL Study Investigators Group: Claire E. Wainwright (Queensland Children's Hospital, Brisbane and The University of Queensland, Brisbane), Keith Grimwood (Griffith University and Gold Coast Health), Joyce Cheney (Queensland Children's Hospital, Brisbane), Narelle George (Pathology Queensland), John B. Carlin (Murdoch Children's Research Institute, Melbourne), Colin F. Robertson (Royal Children's Hospital, Melbourne), Suzanna Vidmar (Murdoch Children's Research Institute, Melbourne), Rosemary Carzino (Murdoch Children's Research Institute, Melbourne), Marj Moodie (Deakin University, Melbourne), David S. Armstrong (Monash Medical Centre, Melbourne), Peter J. Cooper (The Children's Hospital at Westmead, Sydney), A. (James) Martin (Women's & Children's Hospital, Adelaide), Bruce Whitehead (John Hunter Children's Hospital, Newcastle), Catherine A. Byrnes (Starship Children's Hospital and The University of Auckland, Auckland), Harm A.W.M. Tiddens (Erasmus MC, Sophia Children's Hospital, Rotterdam, the Netherlands).

  • The following investigators constitute the CF FAB Study Investigators Group: Claire E. Wainwright (Queensland Children's Hospital, Brisbane and The University of Queensland, Brisbane), Keith Grimwood (Griffith University and Gold Coast Health), Peter D. Sly (The University of Queensland, Brisbane), Harm A.W.M. Tiddens (Erasmus MC, Sophia Children's Hospital, Rotterdam, the Netherlands), Geraint Rogers (SAHMRI and Flinders University School of Medicine, Adelaide), Richard (John) Massie (Royal Children's Hospital, Melbourne), Colin F. Robertson (Royal Children's Hospital, Melbourne), Peter J. Cooper (The Children's Hospital at Westmead, Sydney), Catherine A. Byrnes (Starship Children's Hospital and The University of Auckland, Auckland), Suzanna Vidmar (Murdoch Children's Research Institute, Melbourne), A. (James) Martin (Women's & Children's Hospital, Adelaide), Bruce Whitehead (John Hunter Children's Hospital, Newcastle), David Armstrong (Monash Medical Centre, Melbourne), John B. Carlin (Murdoch Children's Research Institute, Melbourne), Peter Wark (John Hunter Children's Hospital and University of Newcastle, Newcastle).

  • Additional contributions: We are indebted to all current and former clinical and research staff from Queensland Children's Hospital, Brisbane: Nicholas Gailer, Natalie Smith, Careana Moss, Katrina Jess, Peta Yarrow; The Children's Hospital at Westmead, Sydney: Merilyn McArthur, Sam Forbes, Hiran Selvadurai; Royal Children's Hospital, Melbourne: Sarath Ranganathan, Phil Robinson, Natalie Zajakovski; Starship Children's Hospital, Auckland, Jan Tate, Rochelle Moss; Erasmus MC, Sophia Children's Hospital, Rotterdam, the Netherlands: Els Van Der Wiel.

  • Author contributions: Study conception and planning: C.E. Wainwright, S. Vidmar, K. Grimwood, P.D. Sly, C.A. Byrnes, J.B. Carlin, P.J. Cooper, C.F. Robertson, R.J. Massie, M.P.C. Kemner van de Corput, J. Cheney and H.A.W.M. Tiddens. Data collection: C.A. Byrnes, P.J. Cooper, C.F. Robertson, R.J. Massie, JC and C.E. Wainwright. Imaging analysis: N.E. Wijker, M.P.C. Kemner van de Corput and H.A.W.M. Tiddens. Data analysis: statistical analysis led by S. Vidmar with advice from JC. N.E. Wijker, C.E. Wainwright, H.A.W.M. Tiddens and K. Grimwood contributed to planning of statistical analysis. All authors were involved in data interpretation, and preparation, review and approval of the final manuscript.

  • Support statement: This study was supported by grants from the Australian National Health and Medical Research Council (9937868, 351541and 1044829). C.E. Wainwright was supported through Practitioner Fellowship through The Children's Hospital Foundation Brisbane (RG0692016).

  • Conflict of interest: N.E. Wijker reports grants from Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: S. Vidmar reports grants from Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: K. Grimwood reports grants from the Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: P.D. Sly reports grants from Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: C.A. Byrnes reports grants from Australian National Health and Medical Research Council and Faculty Research Development Fund, University of Auckland, New Zealand, during the conduct of the study.

  • Conflict of interest: J.B. Carlin reports grants from Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: P.J. Cooper reports grants from Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: C.F. Robertson reports grants from Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: R.J. Massie reports grants from Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: M.P.C. Kemner van de Corput reports grants from Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: J. Cheney reports grants from Australian National Health and Medical Research Council, during the conduct of the study.

  • Conflict of interest: H.A.W.M. Tiddens reports grants from Australian National Health and Medical Research Council, during the conduct of the study; has provided lectures to Roche and Novartis; grants from CFF, Vertex, Chiesi and Vectura; fees for lectures and advisory board work from Gilead, outside the submitted work; in addition, has a patent PRAGMA-CF scoring system with royalties paid and is heading the Erasmus MC-Sophia Children's Hospital core laboratory lung analysis. FLUIDDA has developed computational fluid dynamic modelling based on chest CTs obtained from Erasmus MC-Sophia for which royalties are received by Sophia Research BV.

  • Conflict of interest: C.E. Wainwright reports grants from Australian National Health and Medical Research Council, during the conduct of the study; and research grants from Vertex Pharmaceuticals Inc., Boehringer Ingelheim and Novo Nordisk Pharmaceuticals; fees for lectures and to attend meetings from Vertex Pharmaceuticals, DKBMed, Novartis Pharmaceuticals, University of Miami, Gilead Sciences Ltd and In Vivo Academy Limited; fees for consultancy, steering committee and advisory board work from Vertex Pharmaceuticals; fees for editorial board work from Thorax; fees for reviewing from BMJ and DKBMed; fees for transport and accommodation from Vertex Pharmaceuticals; and currently holds board positions on the International Advisory Board Vertex Pharmaceuticals P/L, and Associate Editor, Thorax and Respirology.

  • Received August 26, 2019.
  • Accepted December 30, 2019.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 55 Issue 4 Table of Contents
European Respiratory Journal: 55 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort
Naomi E. Wijker, Suzanna Vidmar, Keith Grimwood, Peter D. Sly, Catherine A. Byrnes, John B. Carlin, Peter J. Cooper, Colin F. Robertson, R. John Massie, Mariette P.C. Kemner van de Corput, Joyce Cheney, Harm A.W.M. Tiddens, Claire E. Wainwright
European Respiratory Journal Apr 2020, 55 (4) 1901694; DOI: 10.1183/13993003.01694-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort
Naomi E. Wijker, Suzanna Vidmar, Keith Grimwood, Peter D. Sly, Catherine A. Byrnes, John B. Carlin, Peter J. Cooper, Colin F. Robertson, R. John Massie, Mariette P.C. Kemner van de Corput, Joyce Cheney, Harm A.W.M. Tiddens, Claire E. Wainwright
European Respiratory Journal Apr 2020, 55 (4) 1901694; DOI: 10.1183/13993003.01694-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Asthma medication in obese and healthy weight asthma
  • The impact of COVID-19 on patients with asthma
  • FEV1 decline and cardiovascular disease in COPD
Show more Original Articles

Cystic fibrosis

  • Hyperglycaemia in cystic fibrosis adversely affects BK channel function
  • Assessment lung function changes in cystic fibrosis using 129Xe MRI
  • Multivolume magnetic resonance imaging (1H-MRI) for the longitudinal assessment of cystic fibrosis (CF) lung disease: comparison with spirometry
Show more Cystic fibrosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society